Key Points
- Nurix insider Gwenn Hansen sold 1,452 shares at $25.00 each for $36,300 under a pre-arranged Rule 10b5-1 plan, reducing the position by 1.22% while retaining 117,227 shares.
- Nurix reported a significant quarterly beat, with earnings of $4.73 per share versus an expected $0.60 loss and revenue of $673.06 million versus the $24.35 million consensus estimate.
- Wall Street remains broadly positive, with 13 Buy ratings and a consensus price target of $34.64 versus the recent share price near $24.95; the company also advanced its bexobrutideg program into a Phase 3 trial.
Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) insider Gwenn Hansen sold 1,452 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $25.00, for a total value of $36,300.00. Following the completion of the sale, the insider directly owned 117,227 shares in the company, valued at approximately $2,930,675. The trade was a 1.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gwenn Hansen also recently made the following trade(s):
- On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total value of $36,982.44.
- On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00.
- On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total transaction of $100,143.96.
- On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.
Nurix Therapeutics Price Performance
Shares of NASDAQ NRIX opened at $24.95 on Friday. The stock's 50-day moving average is $25.13 and its two-hundred day moving average is $21.13. Nurix Therapeutics, Inc. has a 1-year low of $9.71 and a 1-year high of $28.23. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 10.80 and a beta of 1.82.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last issued its earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, beating the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a net margin of 42.01% and a return on equity of 49.34%. The firm had revenue of $673.06 million for the quarter, compared to analysts' expectations of $24.35 million. Equities research analysts anticipate that Nurix Therapeutics, Inc. will post 0.85 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on NRIX. UBS Group upped their target price on shares of Nurix Therapeutics from $23.00 to $31.00 and gave the company a "buy" rating in a report on Wednesday, July 22nd. HC Wainwright lifted their price target on shares of Nurix Therapeutics from $32.00 to $34.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. Needham & Company LLC reissued a "buy" rating and issued a $34.00 price target on shares of Nurix Therapeutics in a research report on Tuesday. Robert W. Baird boosted their price target on shares of Nurix Therapeutics from $33.00 to $36.00 and gave the company an "outperform" rating in a research report on Tuesday. Finally, Mizuho upped their price objective on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $34.64.
Get Our Latest Stock Analysis on Nurix Therapeutics
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its position in Nurix Therapeutics by 95.4% during the third quarter. GAMMA Investing LLC now owns 1,270 shares of the company's stock worth $30,000 after buying an additional 620 shares during the period. Nykredit A S purchased a new stake in Nurix Therapeutics in the second quarter valued at approximately $32,000. Integrated Wealth Concepts LLC purchased a new stake in Nurix Therapeutics in the second quarter valued at approximately $33,000. KBC Group NV purchased a new stake in Nurix Therapeutics in the first quarter valued at approximately $34,000. Finally, Avalon Trust Co acquired a new stake in shares of Nurix Therapeutics in the second quarter valued at approximately $64,000.
Nurix Therapeutics News Summary
Here are the key news stories impacting Nurix Therapeutics this week:
- Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst maintained a “Strong Buy” rating, citing promising earlier-stage data, potential accelerated approval and multiple development opportunities. Bexobrutideg clinical analysis
- Positive Sentiment: Analyst sentiment remains broadly bullish. Baird raised its price target to $36 and maintained an “Outperform” rating, while Needham reiterated “Buy” with a $34 target. The consensus target is approximately $34.64, above recent trading levels. Nurix analyst ratings
- Neutral Sentiment: Nurix’s quarterly results significantly exceeded estimates, with earnings of $4.73 per share versus a projected loss of $0.60 and revenue of $673.06 million versus a $24.35 million consensus estimate. However, the earnings reaction was tempered by higher operating expenses as the company continues investing in its pipeline. Nurix quarterly earnings
- Negative Sentiment: Truist reduced its price target for Nurix while retaining a “Buy” rating, signaling more cautious near-term expectations despite confidence in the company’s longer-term prospects. Truist price target update
- Negative Sentiment: Director Julia Gregory sold 22,583 shares for about $528,000, reducing her direct ownership by 67.75%. Separately, insider Gwenn Hansen sold 1,452 shares for $36,300 under a pre-arranged Rule 10b5-1 plan. While planned sales may reflect diversification or personal financial needs, the transactions can weigh on investor sentiment. Nurix insider sale filing
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.
Nurix's pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton's tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
